Top 10 best-selling vaccines of 2013

The vaccine market has long been dominated by the Big 3--Sanofi ($SNY), Merck ($MRK) and GlaxoSmithKline ($GSK)--with Pfizer ($PFE) and Novartis ($NVS) trailing the trio on the list of revenue-generators. But things are changing at the top. The "go big or go home" mentality has sent Novartis packing, with the Swiss company selling GSK most of its vaccines unit earlier this year as it made moves to exit the space. Pfizer, on the other hand, is scouting for ways to bulk up, earlier this month listing AstraZeneca's ($AZN) vaccine assets among the benefits of a potential merger.

For now, though, behind Pfizer's market-leading Prevnar 13, it's jabs from the leading triumvirate that bring in the bulk of vaccine sales. Merck, in particular, took four of the 10 top-selling spots, with Glaxo and Sanofi nabbing two apiece.

But like the list of vaccine heavyweights, the list of top-performing products has seen some shuffling as of late. Take a look at our table of those that enjoyed the most top-line success in 2013--assembled using data from EvaluatePharma--and if you'd like, compare it with the first-half data from the year prior.

And, as always, give us a shout if you've got something to say about it. -- Carly Helfand (email | Twitter)

Top 10 best-selling vaccines of 2013
2013 worldwide sales
1. Prevnar 13 $4.048 billion Pneumococcal infection
2. Gardasil $2.167 billion Human papillomavirus (HPV)
3. PENTAct-HIB $1.525 billion Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B
4. Fluzone/Vaxigrip $1.396 billion Influenza
5. Varivax $1.377 billion Varicella virus
6. Pediarix $1.349 billion Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio
7. Hepatitis vaccine franchise $984 million Hepatitis A; hepatitis B
8. Zostavax $826 million Shingles; herpes
9. RotaTeq $691 million Rotaviral gastroenteritis
10. Pneumovax $653 million Pneumococcal infection
Source: EvaluatePharma


Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.